Granulocyte colony stimulating factor therapy for acute myocardial infarction

Area of Science:

• Cardiology
• Regenerative Medicine
• Clinical Trials

Background:

• Acute myocardial infarction (AMI) causes significant mortality, with current treatments unable to regenerate damaged heart muscle.
• Stem cells, potentially mobilized by granulocyte colony stimulating factor (G-CSF), offer a promising avenue for myocardial regeneration.
• Investigating G-CSF's role in mobilizing stem cells for AMI treatment is crucial.

Purpose of the Study:

• To evaluate the effectiveness of G-CSF therapy in mobilizing stem cells for patients diagnosed with AMI.
• To assess the impact of G-CSF on clinical outcomes and cardiac function in AMI patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing G-CSF to placebo in AMI patients.
• Searched multiple databases including CENTRAL, MEDLINE, EMBASE, BIOSIS, and ISI Web of Science.
• Included trials with daily G-CSF doses (2.5-10 µg/kg) for 4-6 days; data extraction focused on efficacy and safety.

Main Results:

• Seven RCTs involving 354 participants were analyzed; G-CSF showed no significant difference in mortality rates compared to placebo.
• No significant improvements were observed in left ventricular ejection fraction, end-systolic volume, or end-diastolic volume.
• Limited data precluded definitive conclusions on G-CSF safety, and trials lacked sufficient follow-up duration.

Conclusions:

• Current limited evidence from small trials suggests G-CSF therapy offers no clear benefit for AMI patients.
• Methodological limitations, including inconclusive blinding data and short follow-up periods, necessitate larger, robust RCTs.
• Further research is required to ascertain the clinical efficacy and safety of G-CSF treatment in AMI.